Breakthrough T1D celebrates the authorization of the first COVID-19 vaccine by the U.S. Food and Drug Administration, which we hope will be one of many available in the weeks to come to address this deadly pandemic. We appreciate the many research scientists, clinical trial participants, industry partners and government officials who are making this progress possible.
COVID-19 has taken a significant toll on the diabetes community. A new study shows that people who get COVID and have diabetes, whether type 1 or type 2, have three to four times higher risk of severe illness and hospitalization. Based on this evidence, Breakthrough T1D calls upon health care decision makers to make people with type 1 or type 2 diabetes as well as their caregivers a high priority for receiving COVID-19 vaccines.
